View Prospectus

Download Prospectus

 

 

Terms and Conditions

 

NuCannaCo Science Limited (ACN 607 640 513) (NuCannaCo Science Limited) has lodged an Offer Document (Prospectus) with the Australian Securities and Investments Commission (ASIC), a copy of which is available on this website, the date being that shown in Section 1.3 of said Prospectus.

 

Neither ASIC nor NSX Limited takes any responsibility for the contents of the Prospectus or for the merits of the investment to which it relates.

 

The Prospectus does not constitute an offer in any place where, or to any person to whom, it would not be lawful to make such an offer. No action has been taken to register or qualify NuCannaCo Science Limited or the offer or to otherwise permit an offering of NuCannaCo Science Limited in any jurisdiction outside Australia.

 

The distribution of the Prospectus (including an electronic copy) outside Australia may be restricted by law. If you come into possession of the Prospectus, you should observe any such restrictions and should seek your own advice on those restrictions. Any failure to comply with such restrictions may contravene applicable securities laws. The return of a duly completed application form issued with the Prospectus will be taken by NuCannaCo Science Limited to constitute a representation and a warranty made by the applicant to NuCannaCo Science Limited that there has been no breach of such laws and that all necessary approvals and consents have been obtained.

 

NuCannaCo Science Limited will not accept applications for shares offered under the Prospectus during the exposure period (ie the period between the date of lodgement of the Prospectus with NSX and ending seven days after such lodgement, unless the period is extended by ASIC in which event it means the extended period), and no preference will be conferred on applications received in the exposure period.

 

The purpose of the exposure period is to enable the disclosure documents to be examined by market participants prior to the raising of funds. This examination may result in the identification of deficiencies in the Prospectus and in those circumstances, any application that has been received may need to be dealt with in accordance with section 724 of the Corporations Act 2001 (Cth).

 

Neither the Prospectus nor NuCannaCo Science Limited have been, or will be, registered under the United States Securities Act of 1933, as amended (US Securities Act) or the securities laws of any state or other jurisdiction of the United States. The shares may not be offered, sold or resold in the United States or to, or for the account or benefit of, a US Person. The Prospectus does not constitute an offer of securities in the United States or to any US Persons, or to any person acting for the account or benefit of a US Person.

 

You should ensure that any copy of the Prospectus you view or print is complete. To the extent permitted by law, NuCannaCo Science Limited is not liable for any loss incurred from accessing or downloading the Prospectus from this website, including, but not limited to, data corruption on download.

 

Investors should only rely on the Prospectus if they are satisfied that they have accessed the entire document. Please ensure you read the Prospectus in full before deciding to invest.   This notice does not form part of the Prospectus. You must read it before you attempt to access the electronic version of the Prospectus on this website and indicate your agreement or otherwise at the bottom of this notice.

 

Potential investors should read the entire Prospectus carefully before deciding whether to invest in NuCannaCo Science Limited. The Prospectus contains important information about the risks associated with an investment in NuCannaCo Science Limited (see Section 10). The Prospectus does not take into account the investment objectives, financial situation and particular needs of each potential investor (including financial and tax issues). You should contact your financial adviser or other professional adviser before you decide whether to invest in NuCannaCo Science Limited.